The pharmacokinetics of fosfestrol and diethylstilbestrol in chronic hemodialysis patients with prostate cancer

Abstract Background: Fosfestrol drip infusion therapy is an available endocrinotherapy for prostate cancer. But since there have been few reports of its use in chronic dialysis patients, the pharmacokinetics of fosfestrol in these patients remains unclear. We conducted fosfestrol drip infusion therapy as an induction therapy in chronic hemodialysis patients with prostate cancer.

[1]  T. Akiba,et al.  An Overview of Dialysis Treatment in Japan (as of Dec. 31, 1999) , 2001 .

[2]  H. Yamanaka,et al.  Reduction rates of leuprorelin acetate concentration after hemodialysis in a case of prostate cancer associated with chronic renal failure , 1998 .

[3]  K. Saruki,et al.  Leuprorelin acetate blood levels and dialysance after the administration of sustained‐release leuprorelin acetate in a dialysis case complicated by prostate cancer , 1998, The Prostate.

[4]  日本透析医学会統計調査委員会.  An overview of dialysis treatment in Japan (as of Dec. 31, 1996) , 1998 .

[5]  R. Marcén,et al.  Decrease in the haemoglobin level in haemodialysis patients undergoing antiandrogen therapy. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  H. Mizusawa,et al.  [Luteinizing hormone-releasing hormone for prostate cancer in a hemodialysis patient: a case report]. , 1997, Hinyokika kiyo. Acta urologica Japonica.

[7]  Naoko Konno,et al.  Carcinoma of the prostate detected by digital rectal examination in a chronic hemodialysis patient , 1996 .

[8]  I. Sasagawa,et al.  Prostatic cancer in a patient on long-term hemodialysis. , 1991, Nephron.

[9]  F. Port,et al.  Neoplasms in dialysis patients: a population-based study. , 1989, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  U. Dunzendorfer,et al.  New Results on the Pharmacokinetics of Fosfestrol , 1988 .

[11]  中村 浩二.  Bioavailability, distribution and pharmacokinetics of diethylstilbestrol converted from diethylstilbestrol diphosphate in patients with prostatic cancer , 1987 .

[12]  K. Nakamura.  Bioavailability, distribution and pharmacokinetics of diethylstilbestrol converted from diethylstilbestrol diphosphate in patients with prostatic cancer. , 1986, Hiroshima journal of medical sciences.

[13]  T. Agishi,et al.  Malignant tumours in dialysis patients: a nationwide survey. , 1981, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association.